中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2014年
27期
12-13
,共2页
低分子肝素%原发性肾病综合征%儿童
低分子肝素%原髮性腎病綜閤徵%兒童
저분자간소%원발성신병종합정%인동
Low molecular heparin%Primary Nephrotic Syndrome%Children
目的:探讨百令胶囊联合应用低分子肝素治疗儿童原发性肾病综合征的临床效果。方法将112例原发性肾病综合征患儿随机分为两组,对照着患儿采用常规对症支持治疗,治疗组在此基础上加用百令胶囊联合应用低分子肝素进行治疗,观察两组患儿的疗效,生化指标及凝血指标的变化。结果治疗组显效率明显高于对照组,差异有显著的统计学意义(P<0.01),并且在而治疗后治疗组在hs-CRP、24h尿蛋白、TG、Chol、FIB水平明显低于对照组,而ALB,APTT水平明显高于对照组,差异有明显的统计学意义(P<0.05)。结论百令胶囊联合应用低分子肝素治疗儿童原发性肾病综合征安全有效,值得临床推广应用。
目的:探討百令膠囊聯閤應用低分子肝素治療兒童原髮性腎病綜閤徵的臨床效果。方法將112例原髮性腎病綜閤徵患兒隨機分為兩組,對照著患兒採用常規對癥支持治療,治療組在此基礎上加用百令膠囊聯閤應用低分子肝素進行治療,觀察兩組患兒的療效,生化指標及凝血指標的變化。結果治療組顯效率明顯高于對照組,差異有顯著的統計學意義(P<0.01),併且在而治療後治療組在hs-CRP、24h尿蛋白、TG、Chol、FIB水平明顯低于對照組,而ALB,APTT水平明顯高于對照組,差異有明顯的統計學意義(P<0.05)。結論百令膠囊聯閤應用低分子肝素治療兒童原髮性腎病綜閤徵安全有效,值得臨床推廣應用。
목적:탐토백령효낭연합응용저분자간소치료인동원발성신병종합정적림상효과。방법장112례원발성신병종합정환인수궤분위량조,대조착환인채용상규대증지지치료,치료조재차기출상가용백령효낭연합응용저분자간소진행치료,관찰량조환인적료효,생화지표급응혈지표적변화。결과치료조현효솔명현고우대조조,차이유현저적통계학의의(P<0.01),병차재이치료후치료조재hs-CRP、24h뇨단백、TG、Chol、FIB수평명현저우대조조,이ALB,APTT수평명현고우대조조,차이유명현적통계학의의(P<0.05)。결론백령효낭연합응용저분자간소치료인동원발성신병종합정안전유효,치득림상추엄응용。
Objective To investigate the effects of Bailing capsule combined with low molecular heparin on children diagnosed with primary nephrotic syndrome. Methods 112cases of primary nephrotic syndrome children were randomly divided into two groups, patients in control received conventional treatment, the patients in treatment group based on the combined with Bailing capsule combined with low molecular weight heparin for treatment, two groups were observed in clinical, biochemical index and the change of coagulation indexes. Results The treatment group showed significantly higher efficiency compared to the control group, there was significant difference is statistically significant(P<0.01), and in the treatment after the treatment group in the hs-CRP,24h urine protein, TG, Chol, FIB levels were significantly lower than that of the control group, while the ALB, APTT levels were significantly higher than those in the control group, there was statistically significant difference(P<0.05). Conclusion The application of Bailing capsule combined with low molecular heparin in the treatment of children with primary nephrotic syndrome is safe and effective, worthy of clinical application.